Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michaele Roemmele"'
Autor:
Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina de Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus van Dongen, Ekkehard Moessner, Pablo Umaña
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://doaj.org/article/a319ded80cfa47ca96224b37437a82ff
Autor:
Sabine Lang, Guus A.M.S. van Dongen, Oliver Ast, Tapan K. Nayak, Heather Hinton, Erwin van Puijenbroek, Hofer Thomas U, Michaele Roemmele, Peter Brünker, Ingo H. Gorr, Samuel Moser, Marije Bolijn, Sebastian Neumann, Jörg Benz, Flavio Crameri, Ekkehard Moessner, Martine Stihle, Danielle J. Vugts, Maria Cristina De Vera Mudry, Marina Bacac, David Wittig, Pablo Umana, Inja Waldhauer, Jose Saro, Anne Freimoser-Grundschober, Christian Klein, Claire Dunn, Stefan Evers, Nicolini Valeria G, Christian Gerdes
Publikováno v:
OncoImmunology, 6(3):e1277306. Landes Bioscience
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94cba31a29a6556c5c8828f4eec574f
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf